Cédric Révil
About
Cédric Révil is a scholar working on Genetics, Oncology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Cédric Révil has authored 23 papers receiving a total of 807 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 11 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Cédric Révil's work include Glioma Diagnosis and Treatment (11 papers), Radiomics and Machine Learning in Medical Imaging (6 papers) and Cancer Treatment and Pharmacology (6 papers). Cédric Révil is often cited by papers focused on Glioma Diagnosis and Treatment (11 papers), Radiomics and Machine Learning in Medical Imaging (6 papers) and Cancer Treatment and Pharmacology (6 papers). Cédric Révil collaborates with scholars based in Switzerland, Germany and France. Cédric Révil's co-authors include A. Feyereislova, Michaela Lehle, Ashok K. Vaid, Michaela K. Jahn, Alison Jones, Sergei Tjulandin, Bella Kaufman, Michael Clemens, John R. Mackey and P. P. Bapsy and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer Research.
In The Last Decade
Cédric Révil
20 papers receiving 785 citations
Hit Papers
Peers
Cédric Révil
Daniel C. Koboldt United States
M. Beeram United States
Noah Goodman United States
J. Goeminne Belgium
Sharon Wilks United States
P. Gómez Pardo Spain
Senthil Damodaran United States
Jorge Chaves United States
Andrew Koustenis United States
Ivonne Villalobos United States
Citations per year, relative to Cédric Révil Cédric Révil (= 1×)
peers
Daniel C. Koboldt
Countries citing papers authored by Cédric Révil
Since
Specialization
Citations
This map shows the geographic impact of Cédric Révil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cédric Révil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cédric Révil more than expected).
Fields of papers citing papers by Cédric Révil
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Cédric Révil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cédric Révil. The network helps show where Cédric Révil may publish in the future.
Co-authorship network of co-authors of Cédric Révil
This figure shows the co-authorship network connecting the top 25 collaborators of Cédric Révil. A scholar is included among the top collaborators of Cédric Révil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cédric Révil. Cédric Révil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Press, David J., et al.. (2023). Population-level impact of adjuvant trastuzumab emtansine on the incidence of metastatic breast cancer: an epidemiological prediction model of women with HER2-positive early breast cancer and residual disease following neoadjuvant therapy. Breast Cancer. 31(1). 84–95.
2.
Miguel, L. Silva, et al.. (2022). POSB51 A Cost-Effectivess Analysis of Trastuzumab Emtansine Versus Trastuzumab for the Adjuvant Treatment of Patients with Residual Invasive HER2-Positive Breast Cancer in Portugal. Value in Health. 25(1). S69–S70.
3.
Younis, T., et al.. (2020). Economic Evaluation of Adjuvant Trastuzumab Emtansine in Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease after Neoadjuvant Taxane and Trastuzumab–Based Treatment in Canada. Current Oncology. 27(6). 578–589.
4.
Révil, Cédric, Markus Niggli, Sammy Chebon, et al.. (2019). Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Current Medical Research and Opinion. 35(12). 2079–2087.
5.
Révil, Cédric, et al.. (2019). Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): An epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR). Annals of Oncology. 30. v65–v65.
6.
Lear, John T., Nicole Basset‐Séguin, Martin Kaatz, et al.. (2017). Treatment patterns and outcomes for patients with locally advanced basal cell carcinoma before availability of Hedgehog pathway inhibitors: a retrospective chart review. European Journal of Dermatology. 27(4). 386–392.
7.
Nowosielski, Martha, Benjamin M. Ellingson, Olivier Chinot, et al.. (2017). Radiologic progression of glioblastoma under therapy—an exploratory analysis of AVAglio. Neuro-Oncology. 20(4). 557–566.
8.
Wolf, Jennifer Moriatis, In‐Jae Oh, Julien Mazières, et al.. (2016). ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi449–vi449.
9.
Wick, Wolfgang, Olivier Chinot, Martin Bendszus, et al.. (2016). Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro-Oncology. 18(10). 1434–1441.
10.
Chinot, Olivier, Ryo Nishikawa, Warren Mason, et al.. (2016). Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro-Oncology. 18(9). 1313–1318.
11.
Ellingson, Benjamin M., Josep Garcia, Cédric Révil, et al.. (2016). Residual tumor volume and change in tumor volume during adjuvant therapy to predict long-term survival in AVAglio: Phase 3 newly diagnosed glioblastoma patients treated with radiation, temozolomide, and bevacizumab or placebo.. Journal of Clinical Oncology. 34(15_suppl). 2021–2021.
12.
Chinot, Olivier, Josep Garcia, Sylvie Romain, et al.. (2016). ACTR-19. BASELINE PLASMA MATRIX METALLOPROTEINASE 9 (MMP9) PREDICTS OVERALL SURVIVAL (OS) BENEFIT FROM BEVACIZUMAB INDEPENDENTLY OF MOLECULAR SUBTYPES IN NEWLY DIAGNOSED GLIOBLASTOMA: RETROSPECTIVE ANALYSIS OF AVAglio. Neuro-Oncology. 18(suppl_6). vi5–vi5.
13.
Zafar, S. Yousuf, Joleen M. Hubbard, Eric Van Cutsem, et al.. (2015). LBA-01 Survival outcomes according to body mass index (BMI): results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer (mCRC). Annals of Oncology. 26. iv117–iv117.
14.
Mason, Warren, Timothy F. Cloughesy, Wolfgang Wick, et al.. (2014). Overview of Arterial Thromboembolic Events (ATEs) in AVAglio, a Randomized, Placebo-controlled Phase III Trial of Bevacizumab, Radiotherapy and Temozolomide (BEV+RT/TMZ) for Newly Diagnosed Glioblastoma (S22.003). Neurology. 82(10_supplement).
15.
Chinot, Olivier, Wolfgang Wick, Martin J. van den Bent, et al.. (2014). AT-17 * RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology. 16(suppl 5). v12–v12.
16.
Wick, Wolfgang, Olivier Chinot, Warren Mason, et al.. (2014). Patterns of tumor progression in a phase 3 study of bevacizumab (Bv) plus radiotherapy (RT) plus temozolomide (T) for newly diagnosed glioblastoma (GB).. Journal of Clinical Oncology. 32(15_suppl). 2051–2051.
17.
Cloughesy, Timothy F., Wolfgang Wick, Warren Mason, et al.. (2014). AT-18 * SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM]). Neuro-Oncology. 16(suppl 5). v12–v12.
18.
Brandes, Alba A., Warren Mason, Josef Pichler, et al.. (2014). Can Bevacizumab Prolong Survival for Glioblastoma Patients Through Multiple Lines of Therapy?. Future Oncology. 10(7). 1137–1145.
19.
Lee, Eui‐Kyung, Cédric Révil, J. Lister, et al.. (2012). Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea. Clinical Therapeutics. 34(6). 1408–1419.
20.
Kaufman, Bella, John R. Mackey, Michael Clemens, et al.. (2009). Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study. Journal of Clinical Oncology. 27(33). 5529–5537.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Daniel C. Koboldt Breakdown of academic impact, for papers by M. Beeram Breakdown of academic impact, for papers by Noah Goodman Breakdown of academic impact, for papers by J. Goeminne Breakdown of academic impact, for papers by Sharon Wilks Breakdown of academic impact, for papers by P. Gómez Pardo Breakdown of academic impact, for papers by Senthil Damodaran Breakdown of academic impact, for papers by Jorge Chaves Breakdown of academic impact, for papers by Andrew Koustenis Breakdown of academic impact, for papers by Ivonne Villalobos